Scientists have used a gene-editing technique to make mosquitos allies in the fight against malaria. Environmentalists are troubled by the idea of genetically modifying wild animals.
The new mask policy will apply to employees in Arizona, Colorado, Nevada, Texas and Utah. Employees in California and Oregon can choose to wear a company-provided N95 mask.
Since the war began, there's been concern about getting Ukrainian grain to countries in need. A deal was struck in 2022 to keep exports flowing — but Russia put an end to it on Monday.
The recently approved contraception Opill should be available for consumers next year. It's not clear how or whether insurance will cover it. Here's what's known so far.
It's taking off around the country: Treatment at home for patients sick enough to be in a hospital, but stable enough to be home. Are family caregivers ready for all the responsibility?
One North Carolina family's six-figure medical bill came from a state hospital. The attorney general, who is running for governor and says he's against high medical costs, tried to collect the debt.
"If the Children’s Hospital of Georgia would like to be a place of wellness and healing, it should provide only affordable, plant-based options that can help people prevent diabetes, reduce high blood pressure and maintain a healthy weight, among other benefits," according to registered dietitians, doctors and nutrition experts with the Physicians Committee for Responsible Medicine.
Grace Go, a 17-year-old rising senior at Mercer Island High School outside Seattle, is the winner of the first-ever Best Mental Health Podcast Prize from NPR's Student Podcast Challenge.
Below the Belt highlights patients' stories and the push for new research dollars for this poorly understood disease. Here are seven surprising facts from the film.
Fulton County Department of Senior Services is recruiting older volunteers for a new program to help people live safe and healthy lives as they age at home.
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
